Cargando…

Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus

Apoptosis is a fundamental host defence mechanism against invading microbes. Inactivation of NF-κB attenuates encephalomyocarditis virus (EMCV) virulence by triggering rapid apoptosis of infected cells, thereby pre-emptively limiting viral replication. Recent evidence has shown that hypoxia-inducibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Roos, Frederik C, Roberts, Andrew M, Hwang, Irene I L, Moriyama, Eduardo H, Evans, Andrew J, Sybingco, Stephanie, Watson, Ian R, Carneiro, Leticia A M, Gedye, Craig, Girardin, Stephen E, Ailles, Laurie E, Jewett, Michael A S, Milosevic, Michael, Wilson, Brian C, Bell, John C, Der, Sandy D, Ohh, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: WILEY-VCH Verlag 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377327/
https://www.ncbi.nlm.nih.gov/pubmed/20623734
http://dx.doi.org/10.1002/emmm.201000081
_version_ 1782235939992502272
author Roos, Frederik C
Roberts, Andrew M
Hwang, Irene I L
Moriyama, Eduardo H
Evans, Andrew J
Sybingco, Stephanie
Watson, Ian R
Carneiro, Leticia A M
Gedye, Craig
Girardin, Stephen E
Ailles, Laurie E
Jewett, Michael A S
Milosevic, Michael
Wilson, Brian C
Bell, John C
Der, Sandy D
Ohh, Michael
author_facet Roos, Frederik C
Roberts, Andrew M
Hwang, Irene I L
Moriyama, Eduardo H
Evans, Andrew J
Sybingco, Stephanie
Watson, Ian R
Carneiro, Leticia A M
Gedye, Craig
Girardin, Stephen E
Ailles, Laurie E
Jewett, Michael A S
Milosevic, Michael
Wilson, Brian C
Bell, John C
Der, Sandy D
Ohh, Michael
author_sort Roos, Frederik C
collection PubMed
description Apoptosis is a fundamental host defence mechanism against invading microbes. Inactivation of NF-κB attenuates encephalomyocarditis virus (EMCV) virulence by triggering rapid apoptosis of infected cells, thereby pre-emptively limiting viral replication. Recent evidence has shown that hypoxia-inducible factor (HIF) increases NF-κB-mediated anti-apoptotic response in clear-cell renal cell carcinoma (CCRCC) that commonly exhibit hyperactivation of HIF due to the loss of its principal negative regulator, von Hippel–Lindau (VHL) tumour suppressor protein. Here, we show that EMCV challenge induces a strong NF-κB-dependent gene expression profile concomitant with a lack of interferon-mediated anti-viral response in VHL-null CCRCC, and that multiple established CCRCC cell lines, as well as early-passage primary CCRCC cultured cells, are acutely susceptible to EMCV replication and virulence. Functional restoration of VHL or molecular suppression of HIF or NF-κB dramatically reverses CCRCC cellular susceptibility to EMCV-induced killing. Notably, intratumoural EMCV treatment of CCRCC in a murine xenograft model rapidly regresses tumour growth. These findings provide compelling pre-clinical evidence for the usage of EMCV in the treatment of CCRCC and potentially other tumours with elevated HIF/NF-κB-survival signature.
format Online
Article
Text
id pubmed-3377327
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher WILEY-VCH Verlag
record_format MEDLINE/PubMed
spelling pubmed-33773272012-09-17 Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus Roos, Frederik C Roberts, Andrew M Hwang, Irene I L Moriyama, Eduardo H Evans, Andrew J Sybingco, Stephanie Watson, Ian R Carneiro, Leticia A M Gedye, Craig Girardin, Stephen E Ailles, Laurie E Jewett, Michael A S Milosevic, Michael Wilson, Brian C Bell, John C Der, Sandy D Ohh, Michael EMBO Mol Med Research Articles Apoptosis is a fundamental host defence mechanism against invading microbes. Inactivation of NF-κB attenuates encephalomyocarditis virus (EMCV) virulence by triggering rapid apoptosis of infected cells, thereby pre-emptively limiting viral replication. Recent evidence has shown that hypoxia-inducible factor (HIF) increases NF-κB-mediated anti-apoptotic response in clear-cell renal cell carcinoma (CCRCC) that commonly exhibit hyperactivation of HIF due to the loss of its principal negative regulator, von Hippel–Lindau (VHL) tumour suppressor protein. Here, we show that EMCV challenge induces a strong NF-κB-dependent gene expression profile concomitant with a lack of interferon-mediated anti-viral response in VHL-null CCRCC, and that multiple established CCRCC cell lines, as well as early-passage primary CCRCC cultured cells, are acutely susceptible to EMCV replication and virulence. Functional restoration of VHL or molecular suppression of HIF or NF-κB dramatically reverses CCRCC cellular susceptibility to EMCV-induced killing. Notably, intratumoural EMCV treatment of CCRCC in a murine xenograft model rapidly regresses tumour growth. These findings provide compelling pre-clinical evidence for the usage of EMCV in the treatment of CCRCC and potentially other tumours with elevated HIF/NF-κB-survival signature. WILEY-VCH Verlag 2010-07 /pmc/articles/PMC3377327/ /pubmed/20623734 http://dx.doi.org/10.1002/emmm.201000081 Text en Copyright © 2010 EMBO Molecular Medicine
spellingShingle Research Articles
Roos, Frederik C
Roberts, Andrew M
Hwang, Irene I L
Moriyama, Eduardo H
Evans, Andrew J
Sybingco, Stephanie
Watson, Ian R
Carneiro, Leticia A M
Gedye, Craig
Girardin, Stephen E
Ailles, Laurie E
Jewett, Michael A S
Milosevic, Michael
Wilson, Brian C
Bell, John C
Der, Sandy D
Ohh, Michael
Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus
title Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus
title_full Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus
title_fullStr Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus
title_full_unstemmed Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus
title_short Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus
title_sort oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377327/
https://www.ncbi.nlm.nih.gov/pubmed/20623734
http://dx.doi.org/10.1002/emmm.201000081
work_keys_str_mv AT roosfrederikc oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT robertsandrewm oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT hwangireneil oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT moriyamaeduardoh oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT evansandrewj oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT sybingcostephanie oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT watsonianr oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT carneiroleticiaam oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT gedyecraig oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT girardinstephene oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT ailleslauriee oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT jewettmichaelas oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT milosevicmichael oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT wilsonbrianc oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT belljohnc oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT dersandyd oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus
AT ohhmichael oncolytictargetingofrenalcellcarcinomaviaencephalomyocarditisvirus